

The New Jersey Journal of Pharmacy

Author Guidelines

Manuscript Submission

All journal article submissions should be emailed to njpharmacists@gmail.com

The NJPhA Journal of Pharmacy thanks you for your submission for publication. We publish a quarterly journal comprising a Winter, Spring, Summer and Fall edition. All submissions will undergo a review process. After completion of the review process, an acceptance or rejection will be communicated to the corresponding author via email. Please note submission does not guarantee publication in the upcoming issue.

Manuscript Guidelines

Cover Page

All submissions must include a completed cover page and disclosure statement. The cover page and disclosure statements can be found at the end of this document

Content Categories and Recommended Word Limits

All submissions must be categorized into one of the content categories listed below. Each content category has a mandatory word limit. Word count limits do not include tables, graphs, or figures.

- **Original Research Report – Word limit: 2500.** Organized into the following subsections: Background/Purpose, Methods, Results, Discussion, and Conclusion. Include 250 word abstract at the beginning of your manuscript (sections: background, methods, discussion, conclusion).
- **Drug or Therapeutic Review – Word limit: 2500.** Should be comprehensive and contain essential information on a particular subject relevant to the profession of pharmacy. Include 250 word abstract at the beginning of your manuscript (sections: background, methods, discussion, conclusion).
- **Case Report or Case Study – Word limit: 1500.** Consists of unique patient case(s) that are of interest to pharmacists.
- **Pharmacy practice spotlight – Word limit: 1500.** Highlights a particular pharmacy practice in New Jersey that demonstrates advances in care or provides specialized care.
- **Editorial or Commentary – Word limit: 750.** Should focus on areas related to clinical pharmacy practice, research, or education. Authors interested in pursuing ideas that fall outside these categories should contact the editors, at njpharmacists@gmail.com

Acknowledgments

Individuals who have made significant contributions, but do not qualify as authors, should be acknowledged (if they agree to be named) at the end of the article. For additional information on authorship, consult the International Committee of Medical Journal Editors (ICMJE) authorship criteria.

Permissions

Written proof of permission from the person or entity that holds copyright is necessary to use or adapt previously published tables, figures, or other copyrighted illustrative material. Such re-use or adaptation must be explicated and credited as such.

Style Guidelines

- Manuscript should be prepared in Microsoft Word (no PDFs) using a 12-point font (Times New Roman or Arial font) and an 8.5 x 11.0 inch page size. All pages should be double-spaced and numbered. As submissions will be blinded for review, do not include identifying information anywhere except on the cover page.
- Graphs, tables, and diagrams will be printed in monochrome/grayscale and at a default size of ¼ page. Authors should make sure all details and captions are legible at that scale, in that format, and concise in nature.
- Abbreviations and acronyms should be defined upon first use in the body of the paper.
- The brand name of a product should be followed immediately by the generic name in parentheses. Alternately, the generic name can be followed immediately by at least 2 brand names cited as examples, in parentheses. The generic, not brand, name of a drug should be used consistently in the manuscript. If a brand or generic name for a product is not yet available, use the company code name.
- Discussion should occur in generic, nonspecific terms. For example, authors should avoid mention of the manufacturer by name, the kind of packaging, product-specific handling/administration requirements, or price that is promotional in nature.
- Use: AMA Manual of Style, 10th Ed
<http://www.amamanualofstyle.com/view/10.1093/jama/9780195176339.001.0001/med-9780195176339>
- References:
 - All references must appear in the text as superscripted Arabic numerals, and be cited consecutively. This applies for references in text, tables, and figure legends; reference citations are not used in the abstract.
 - Citation format:
 - Journal names should be abbreviated as they appear in PubMed. Those not appearing in PubMed should be spelled out. Articles "In press" must include the title of the journal that has accepted the paper.
 - List all authors when there are 6 or fewer; with 7 or more authors, list the first 3, followed by et al.
 - Articles that have been published online ahead of print, include the date published online (Epub date) in place of the numerical portion of the citation.
- Citation examples:
 - Articles:
 - Baldwin DS, Heldbo Reines E, Guiton C, Weiller E. Escitalopram therapy for major depression and anxiety disorders. *Ann Pharmacother*. 2007;41:1583-1592.
 - Wormser GP, Ramanathan R, Nowakowski J, et al. Duration of antibiotic therapy for early Lyme disease. *Ann Intern Med*. 2003;138:697-705.

- Cies JJ, Shankar V. Nephrotoxicity in Patients with Vancomycin Trough Concentrations of 15-20 $\mu\text{g/ml}$ in a Pediatric Intensive Care Unit. *Pharmacotherapy*. 2013 Mar 7. [Epub ahead of print]
- Electronic sources:
 - Centers for Disease Control and Prevention. Malaria. <http://www.dpd.cdc.gov/dpdx/HTML/Malaria.htm>. Accessed March 21, 2013.
- Abstracts:
 - Rao N, Knebel W, Bergsma T, et al. Population pharmacokinetics of istradefylline (abstract 13). *J Clin Pharmacol*. 2007;47:1185.
- Books:
 - Goldberg L, Elliot DL. *Exercise for Prevention and Treatment of Illness*. Philadelphia, Pa: FA Davis Co; 1994.
- Book chapter:
 - Gamble VN. On becoming a physician: a dream not deferred. In: White EC, ed. *The Black Women's Health Book: Speaking for Ourselves*. Seattle, Wash: Seal Press; 1990:52-64.
- Prescribing information:
 - Januvia [package insert]. Whitehouse Station, NJ: Merck & Co., Inc.; February 2013.
- Scientific presentation:
 - Davis TM, Yeap B, Bruce DG, Davis WA. Lipid-lowering therapy protects against peripheral sensory neuropathy in type 2 diabetes. Presented at: 67th Scientific Sessions. American Diabetes Association Annual Meeting, Chicago, IL, June 22, 2007.



The New Jersey Journal of Pharmacy Article Cover Sheet

*The information requested below is requested for all contributing authors

Names of authors in order of which they should appear [corresponding author marked with asterisk]:

Phone:

Email:

Affiliations [if applicable]:

Highest academic degree, position title, and/or academic appointment:

Article Title:

I attest that the manuscript I am submitting is my original work and is intended for publication in the New Jersey Journal of Pharmacy exclusively and has not been submitted or published elsewhere.



New Jersey Journal of Pharmacy Disclosure Statement:

To ensure independence in journal article submissions, authors must disclose any real or apparent conflict(s) of interest that may have a direct bearing on the subject matter of the article. Disclosures pertain to relationships with any drug products, pharmaceutical companies, biomedical device manufacturers, or other corporations whose products or services are related to the subject matter of the specific presentation topic. In the event there is a conflict, a suitable acknowledgment or disclaimer must be provided to the readers of the journal. The intent of this policy is not to prevent an author with potential conflict of interest from submitting an article, but rather, it is intended that any potential conflict should be identified openly so readers may form their own judgments about the presentation with full disclosure of the facts. It is up to the reader to determine whether the speaker's outside interests may reflect a possible bias in either the discussion or conclusions presented.

I have no actual or potential conflict of interest in relation to this activity.

Signature

Date

I have or have had a financial interest/arrangement or affiliation with one or more commercial interests that could be perceived as a real or apparent conflict of interest in the context of the subject of this article, including but not limited to: consulting; a family member employed by the organization; a fiduciary responsibility; membership on a governing board; recipient of a grant or research support; a major stockholder; salary, royalty, other financial or material support; and/or membership on a speaker's bureau.

Name of Commercial Interest

Nature of Relationship.

Signature

Date

Checklist for Authors:

- Cover Page
- Disclosure Form
- Manuscript
 - Include abstract if submission is original research or drug/therapeutic review
 - Tables and figures should be included in the manuscript document but starting on a separate page